About the Event
In April of 2020, the FDA published a statement that blood purification devices may be effective at treating certain patients with confirmed COVID-19 by reducing various pathogens, cytokines, and other inflammatory mediators from the bloodstream.
Sigyn Therapeutics [OTC:SIGY] has reported results from a series of in vitro blood purification studies that have validated the ability of Sigyn Therapy to extract viral pathogens including COVID-19 from human blood plasma. Pre-infection preventives like the mRNA vaccines are important, but as additional variants are discovered and people experience breakthrough infections, blood purification technology like Sigyn Therapy could be used to save millions of lives.
Please join our webinar with Sigyn CEO, Jim Joyce. He’ll discuss how a properly designed blood purification device can perform functions that are beyond the reach of drugs and have broad applications for the treatment of pandemic viruses and beyond.